Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 2/20 | 0.51 |
| ▸ | PDXK | O00764 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | WEE1 | P30291 | 1/20 | 0.51 |
| ▸ | NEK3 | P51956 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.51 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.51 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.51 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736469 | 1.00 | PTK2 (0.51) | PTK2PDXKBRD4WEE1NEK3 | |
| SCHEMBL13652983 | 0.87 | IGF1R (0.53) | PTK2PDXKBRD4WEE1NEK3 | |
| SCHEMBL18623963 | 0.87 | IGF1R (0.53) | PTK2PDXKBRD4WEE1NEK3 | |
| SCHEMBL12662354 | 0.86 | PDXK (0.52) | PTK2PDXKBRD4WEE1NEK3 | |
| SCHEMBL736977 | 0.86 | PDXK (0.52) | PTK2PDXKBRD4WEE1NEK3 | |
| SCHEMBL738951 | 0.86 | PDXK (0.52) | PTK2PDXKBRD4WEE1NEK3 | |
| SCHEMBL3487851 | 0.85 | PTK2 (0.48) | PTK2PDXKBRD4WEE1NEK3 | |
| SCHEMBL3487848 | 0.85 | PTK2 (0.48) | PTK2PDXKBRD4WEE1NEK3 | |
| SCHEMBL14110335 | 0.85 | KMT2A (0.55) | BRD4IGF1RPOLBALDH1A1LMNA | |
| SCHEMBL738506 | 0.85 | KMT2A (0.55) | BRD4IGF1RPOLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664222-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-04 | — | — | US | disclosed |
| US-8329695-B2 | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20120214995-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-8188086-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8188086-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8138373-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-8138341-B2 | Intermediate compounds useful for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20100280037-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100249458-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100249412-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-7759485-B2 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | ONCOHEROES BIOSCIENCES INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | ONCOHEROES BIOSCIENCES INC. | 2009-01-29 | — | — | US | disclosed |
| US-7439358-B2 | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | ONCOHEROES BIOSCIENCES INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214995-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | QDPR, REN, DHPS | PTK2 4742/4885PDXK 728/4885BRD4 645/4885 |
| US-20100280037-A1 | CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | QDPR, DHPS, DPYD | PTK2 4757/4885PDXK 334/4885BRD4 2295/4885 |
| US-20070203146-A1 | N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide | DHPS, PKD1, AQP4 | PTK2 4721/4885PDXK 1115/4885BRD4 453/4885 |
| US-20100249458-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | PTK2 4871/4885PDXK 1424/4885BRD4 4869/4885 |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | PTK2 4871/4885PDXK 1424/4885BRD4 4869/4885 |
| US-20100249412-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | PTK2 4871/4885PDXK 1424/4885BRD4 4869/4885 |
| US-20090030004-A1 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE | QDPR, REN, DHPS | PTK2 4742/4885PDXK 728/4885BRD4 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.